MX2013007904A - Anticuerpos anti-il-12/il-23 y usos de los mismos. - Google Patents

Anticuerpos anti-il-12/il-23 y usos de los mismos.

Info

Publication number
MX2013007904A
MX2013007904A MX2013007904A MX2013007904A MX2013007904A MX 2013007904 A MX2013007904 A MX 2013007904A MX 2013007904 A MX2013007904 A MX 2013007904A MX 2013007904 A MX2013007904 A MX 2013007904A MX 2013007904 A MX2013007904 A MX 2013007904A
Authority
MX
Mexico
Prior art keywords
antibodies
residues
epitopes
subunit
antigen
Prior art date
Application number
MX2013007904A
Other languages
English (en)
Spanish (es)
Inventor
Susan E Lacy
David W Borhani
Ramkrishna Sadhukhan
Holly H Soutter
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013007904A publication Critical patent/MX2013007904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013007904A 2011-01-07 2012-01-06 Anticuerpos anti-il-12/il-23 y usos de los mismos. MX2013007904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161460780P 2011-01-07 2011-01-07
PCT/US2012/020529 WO2012094623A2 (en) 2011-01-07 2012-01-06 Anti-il-12/il-23 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2013007904A true MX2013007904A (es) 2013-08-29

Family

ID=46457988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007904A MX2013007904A (es) 2011-01-07 2012-01-06 Anticuerpos anti-il-12/il-23 y usos de los mismos.

Country Status (13)

Country Link
US (1) US20120288494A1 (enExample)
EP (1) EP2661448A4 (enExample)
JP (1) JP2014506132A (enExample)
KR (1) KR20140038369A (enExample)
CN (1) CN103596978A (enExample)
AU (1) AU2012204237A1 (enExample)
BR (1) BR112013017417A2 (enExample)
CA (1) CA2821926A1 (enExample)
MX (1) MX2013007904A (enExample)
RU (1) RU2013136908A (enExample)
SG (1) SG191874A1 (enExample)
TW (1) TW201242976A (enExample)
WO (1) WO2012094623A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500413A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US7776331B1 (en) * 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
NZ602511A (en) 2008-03-18 2014-03-28 Abbvie Inc Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2014228553B2 (en) * 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN105749252B (zh) * 2016-04-29 2025-11-14 南方医科大学 Il-9作为治疗血小板缺少症的药物的应用
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112232A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021018114A1 (zh) * 2019-07-30 2021-02-04 中山康方生物医药有限公司 抗人p40蛋白域抗体及其用途
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20250066441A1 (en) 2021-07-19 2025-02-27 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CA3270918A1 (en) * 2022-10-17 2024-04-25 Rani Therapeutics Llc Dosage Forms and Methods of Ustekinumab
WO2024151978A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
JP3579355B2 (ja) * 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US8080247B2 (en) * 2000-08-07 2011-12-20 Janssen Biotech, Inc. Anti-IL-12 antibodies
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI323734B (en) * 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法

Also Published As

Publication number Publication date
BR112013017417A2 (pt) 2016-09-27
TW201242976A (en) 2012-11-01
WO2012094623A2 (en) 2012-07-12
CA2821926A1 (en) 2012-07-12
EP2661448A4 (en) 2015-09-16
WO2012094623A3 (en) 2012-08-30
NZ611840A (en) 2015-04-24
CN103596978A (zh) 2014-02-19
KR20140038369A (ko) 2014-03-28
JP2014506132A (ja) 2014-03-13
US20120288494A1 (en) 2012-11-15
SG191874A1 (en) 2013-08-30
RU2013136908A (ru) 2015-02-20
EP2661448A2 (en) 2013-11-13
AU2012204237A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
MX2013007904A (es) Anticuerpos anti-il-12/il-23 y usos de los mismos.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2019008303A (es) Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
ZA202001294B (en) Multispecific antibody
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
CA2953714C (en) Anti-tnfa antibodies with ph-dependent antigen binding
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
WO2017015427A8 (en) Methods for improving the efficacy and expansion of immune cells
AU2016249005A8 (en) Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
HK1212711A1 (zh) Bcma抗原結合蛋白
MX2013009362A (es) Anticuerpo contra el csf-1r.
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
WO2013059524A3 (en) Antibodies directed against influenza
MX2012011934A (es) Proteinas de union a amiloide beta.
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
HK1198832A1 (en) Fn14 binding proteins and uses thereof
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2015107363A3 (en) Mycobacterial antigen composition
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
WO2012119004A3 (en) Parathyroid hormone analogs, compositions and uses thereof
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
HK1214279A1 (zh) 組合物和相關的抗原結合蛋白針對il-21受體的方法
WO2013132274A3 (en) Immunological methods of inhibiting gonad maturation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal